B&S Group S.A. announced that the Supervisory Board has appointed Mr. Engelbert Tjeenk Willink as an independent member of the Supervisory Board of B&S and chairperson of the Company's Selection, Appointment and Nomination Committee ("SARCO") with immediate effect. The appointment was made by co-optation in accordance with applicable law and the Company's Articles of Association, to fill the vacancy created by the resignation of former Supervisory Board member and chairperson of the SARCO. As a result, Mr. Tjeenk Willink continues the term of the mandate of his predecessor, ending after the Annual General Meeting to be held in 2025.

The appointment by co-optation of Mr. Engelbert Tjeenk Willink, as well as that of Mr. Derk Doijer announced in a press release on December 19, 2022, will be confirmed at the next General Meeting of the Company. Mr. Tjeenk Willink has significant Supervisory Board membership experience gained in the pharmaceutical, biotech industry and in multiple start-ups in different sectors. He gained 30 years of experience in the pharmaceutical industry, for instance with multinational Boehringer Ingelheim GmbH as Member of the Board of Managing Directors.

He holds a degree in Medicine from the university of Rotterdam. Mr. Tjeenk Willink complies with the independence criteria of the Dutch Corporate Governance Code and the profile drawn up by the Supervisory Board. With his extensive experience in multiple managerial roles within large international organizations and with his broad strategic and operational experience in marketing & sales and business development, he will bring substantial added value to the Supervisory Board.

The Supervisory Board will also continue the recruitment process for a fifth member that is independent under the meaning of the Dutch Corporate Governance Code and to bring necessary balance to the current Supervisory Board composition.